Spectral AI 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Spectral AI said its 3rd quarter 2026 results reflected its transition from a research and development organization to a commercial enterprise.
- Research and development revenue was $2.9 million, down 24.7% from $3.8 million in Q3 2025; BARDA revenue was $2.7 million compared to $3.4 million.
- Revenue from other U.S. government programs, principally the M-Tech Intel device program, was $0.1 million compared to $0.4 million as work under that program was completed.
- Gross margin was 27.2% compared to 42.7%, reflecting Spectral AI's share of development costs with BARDA recorded in cost of revenue.
- Total operating expenses declined 4% to $4.7 million from $5.0 million in Q3 2025; R&D expense increased to $2.0 million from $1.5 million, general and administrative expense decreased to $2.3 million from $3.1 million, and selling and marketing expense increased about $50,000 to $0.4 million.
- Other income was $0.2 million compared to other expense of $0.2 million in Q3 2025, primarily due to a $0.8 million gain from the change in the fair value of warrant liabilities, partially offset by $0.6 million of net interest expense.
- Net loss was $3.7 million, or $0.11 per basic and diluted shares, compared to $3.6 million, or $0.13 per share, in Q3 2025; adjusted EBITDA was a loss of $3.7 million compared to a loss of $3.1 million.
- Cash was $11.2 million as of September 30th, 2026, compared to $15.4 million at December 31st, 2025; the company used $10.5 million in operating activities in the first 9 months of the year, offset by $6.3 million from financing activities.
- The Avenue facility was fully drawn at $15 million, with interest-only payments through March 2027 and maturity in March 2028; Spectral AI had 32.2 million shares outstanding at quarter end.
- Spectral AI began manufacturing the first 30 DeepView AI systems for BARDA-supported deployments at U.S. burn centers and said initial commercial sales remain an achievable goal for 2026.
- In the United Kingdom, the company completed site initiation visits at 4 burn centers and had enrolled 10 patients in a self-funded study to expand its label to include head, hands, and feet burn areas.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this event is being recorded. I would now like to turn the conference over to Devin Sullivan, Managing Director of The Equity Group. Please go ahead. Thank you, Gary.
Good afternoon, everyone, and thank you for joining us for Spectral AI's 2026 third quarter financial results conference call. Our speakers for today will be Vincent Capone, the company's Chief Executive Officer, and David McGuire, Chief Financial Officer. Before we begin, I'd like to remind everyone that during this call, certain statements made are forward-looking statements within the meaning of the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the company's strategy, plans, objectives, initiatives, and financial outlook. When used in this call, the words estimates, projected, expects, anticipates, forecasts, plans, intends, believes, seeks, may, will, should, future, propose, and variations of those words or similar expressions, or the negative versions of such words or expressions, are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside the company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, listeners are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors and other risks and uncertainties described in the risk factor section of the company's filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. With that, I would now like to turn the call over to Vincent Capone, Spectral AI's Chief Executive Officer.
Vince, please go ahead. Thanks, Devin, and thank you all for joining us today.
We issued our earnings release this afternoon, which contains additional details of our operating results, and we will be filing our 10-Q with the SEC on or before November 16 of this year. Our third quarter results reflect the continued transition of Spectral AI from a research and development organization into a commercial enterprise. Commercialization of a new medical technology requires more than regulatory authorization. It requires establishing clinical confidence, expanding our existing relationships with leading burn centers, demonstrating economic value to hospital systems, and ultimately integrating this technology into the clinical workflow. These are precisely the areas where our team is focused. We are making good progress with the initial BARDA-supported deployments of our DeepView AI System for our first commercial sales, which remain an achievable goal for 2026.
To that end, during this quarter, we began manufacturing the first 30 DeepView AI Systems for BARDA-supported deployments at U.S. burn centers. We are encouraged by the engagement we are receiving from burn centers across the country and the progress being made toward expanding our national sales footprint. We believe the clinical infrastructure, relationships, and evidence we are building today are essential to establishing a sustainable and expanding commercial business. Our vision extends beyond simply placing devices in hospitals or burn centers for mass casualty preparedness. While preparedness remains an important component of our strategy, we believe the much greater opportunity is to make this technology available as part of the clinical protocol for everyday burn care. We want to establish a national sales footprint for our DeepView AI System that supports more consistent, objective, and timely burn wound assessments, with the ultimate goal of improving patient outcomes.
We believe patients should have access to the benefits of our advanced diagnostic technology regardless of where they live or which burn center they visit. We are focused on making this technology broadly accessible to patients regardless of the geographic location or socioeconomic status, with a goal of helping ensure more equitable access to advanced burn wound assessment and the highest quality of care. As part of this strategy, we have started clinical studies in the United States and the United Kingdom. In the United Kingdom, we are self-funding a study to expand our label to include head, hands, and feet burn areas. We have completed all site initiation visits at four burn centers in the United Kingdom and have currently enrolled 10 patients already in this label expansion study.
In the United States, to further support the economic development of our DeepView AI System, we are finalizing preparations for our Triage and Treatment Outcomes study, or as we like to call it, the TNT study, which will evaluate DeepView AI's potential to improve surgical precision, accelerate treatment decisions, and reduce hospital length of stay. We expect to commence the TNT study at four to five burn centers in early December of this year, with plans to expand to 12 centers across the United States by the end of the first quarter of 2027. As we work through our commercialization model, we recognize the economic value of reimbursement to both hospital systems and the physicians themselves. We have been working hard to create a heightened reimbursement coding for the use of our device in both inpatient and outpatient settings.
Early in the third quarter, we submitted a new technology add-on payment, or NTAP application, to the Centers for Medicare & Medicaid Services for our DeepView System. If approved, this would provide hospitals with additional Medicare reimbursement for eligible use of the DeepView System, helping to reduce adoption barriers for both eligible health systems, as well as making it easier to integrate and utilize our device in the appropriate inpatient setting. We expect a determination to be made by August of next year. On the physician side, we note that a reimbursement pathway has been advanced as of January 1st, 2027, with pricing supported by local Medicare Administrative Contractor pricing. Our CPT-3 coding, we are working to move to a CPT-1 coding, which will be supported by our TNT study.
We are also continuing to expand the total body surface area burn calculation that uses our DeepView System's imaging and AI platform to quickly and objectively quantify how much of a patient's body is burned. The advancements we are working on will provide a standardized, data-driven input for triage, fluid resuscitation, and treatment decisions, which are especially valuable in complex or mass casualty situations. In connection with our international sales strategies, we are still progressing with updating our UKCA burn assessment approval, which we secured in 2024, to reflect the improved algorithm, hardware, and software that was included in our FDA clearance just this past May. Although we had anticipated receiving clearance by year-end, we now expect this approval in early 2027, after which time we will commence initial sales and placements of the DeepView AI System in either the U.K., Australia, or the Gulf Cooperation Council countries.
We believe our existing relationships with leading global burn centers will also support the initial commercial launch outside of the United States. To date, we have made good progress. Regarding awareness, we are encouraged by our interactions at the Southern Regional Burn Conference in September, where leading burn surgeons presented new study results involving our DeepView AI System. Those presentations addressed physician accuracy in identifying non-healing burns, as well as the repeatability and reproducibility of the DeepView System's AI analysis. Furthermore, in October, we showcased the DeepView AI System at the American College of Emergency Physicians Scientific Assembly in Chicago. This provided yet another opportunity to introduce our technology and discuss its potential role in burn assessment and hear directly from emergency physicians about their clinical needs and how our device supports those requirements.
While the economics of our development work are different from those associated with the commercial business we are building, we remain well-capitalized to execute on our strategic commercial priorities. We ended the quarter with more than $11 million in cash, a manageable debt profile, and access to an additional $90 million of non-dilutive funding from BARDA. As we make this transition from a research organization to a commercial-focused enterprise, we remain disciplined about how we will deploy capital and how we will fund our business and its growth. Our immediate priorities are clear: complete initial manufacturing and begin the initial BARDA-supported sale deliveries of the DeepView AI System across a national footprint, further advance our commercial sales efforts both domestically and internationally, with existing relationships leading to initial sales across both the U.S. and abroad.
We wish to continue to support clinicians as they evaluate and introduce DeepView AI in its clinical workflow, and to continue our reimbursement and label expansion initiatives to support hospitals and physicians. With that, I'm pleased to turn the call over to David McGuire, our Chief Financial Officer.
Thanks, Vince. Before I walk through the numbers, some context on where we are with BARDA. BARDA has supported the development of DeepView AI with approximately $250 million of non-dilutive funding, and that work led to FDA De Novo authorization in May. In June, we completed the base phase of our current BARDA contract and moved into its follow-on development phase. In this phase, the scope narrows to specific development projects, and the costs are shared. BARDA reimburses a portion of our development costs, and we fund the rest. The third quarter was our first full quarter under this phase, and as we noted last quarter, we prepared for it. Research and development revenue for Q3 2026 was $2.9 million, down 24.7% from $3.8 million in Q3 2025. BARDA revenue was $2.7 million compared to $3.4 million, reflecting this narrower scope and the cost share.
Revenue from other U.S. government programs, principally the MTEC handheld device program, was $0.1 million compared to $0.4 million, as work under that program was completed. Gross margin was 27.2% compared to 42.7%, reflecting our share of development costs with BARDA, which is recorded in cost of revenue. Total operating expenses for Q3 2026 declined 4% to $4.7 million from $5.0 million in Q3 2025. While we continue to invest in our commercialization activities, we are managing costs carefully without compromising our ability to execute. Breaking OPEX down by category in Q3 2026 compared to Q3 2025, R&D expense increased to $2.0 million from $1.5 million, primarily from the U.K. label expansion study for burns of the heads, hands, and feet that Vince described. General and administrative expense decreased to $2.3 million from $3.1 million, primarily reflecting lower legal fees and related professional services.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
